These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3910195)

  • 1. A model for tumor response to chemotherapy: an integration of the stem cell and somatic mutation hypotheses.
    Goldie JH; Coldman AJ
    Cancer Invest; 1985; 3(6):553-64. PubMed ID: 3910195
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical implications of tumor-cell heterogeneity.
    Schnipper L
    N Engl J Med; 1986 May; 314(22):1423-31. PubMed ID: 3517651
    [No Abstract]   [Full Text] [Related]  

  • 3. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting leukemia stem cells.
    Mikkola HK; Radu CG; Witte ON
    Nat Biotechnol; 2010 Mar; 28(3):237-8. PubMed ID: 20212485
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer stem cells: a step toward the cure.
    Boman BM; Wicha MS
    J Clin Oncol; 2008 Jun; 26(17):2795-9. PubMed ID: 18539956
    [No Abstract]   [Full Text] [Related]  

  • 6. Experimental basis of antileukaemic chemotherapy.
    Messner HA
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():20-5. PubMed ID: 2653504
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of colony-stimulating activities for evaluating in vitro granulomonopoiesis in normal subjects and in patients with myeloid leukemias.
    López-Karpovitch X; Padrós-Semorile MR; Hurtado-Monroy R; Cárdenas MR; Niesvizky N; Martínez-Sánchez L; Rojas R
    Rev Invest Clin; 1985; 37(4):323-7. PubMed ID: 3879370
    [No Abstract]   [Full Text] [Related]  

  • 8. On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future).
    Skipper HE
    Bull Math Biol; 1986; 48(3-4):253-78. PubMed ID: 3828557
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of drug resistance in cultured clonogenic leukemic blast cells during the clinical course of myeloblastic leukemia.
    Asano Y; Okamura S; Shibuya T; Morioka E; Hirota Y; Niho Y
    Oncology; 1989; 46(5):339-42. PubMed ID: 2779949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in growth parameters and their effect on the acquisition of drug resistance.
    Coldman AJ; Goldie JH
    Prog Clin Biol Res; 1986; 223():103-11. PubMed ID: 3809192
    [No Abstract]   [Full Text] [Related]  

  • 11. [Development of therapeutic strategies targeting AML stem cells].
    Ishikawa F
    Nihon Rinsho; 2014 Jun; 72(6):992-6. PubMed ID: 25016794
    [No Abstract]   [Full Text] [Related]  

  • 12. Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.
    Mony U; Jawad M; Seedhouse C; Russell N; Pallis M
    Leukemia; 2008 Jul; 22(7):1395-401. PubMed ID: 18509353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between the secondary colony-plating efficiency of blast progenitors and the remission induction outcome of acute myeloblastic leukemia patients.
    Nara N
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1624-9. PubMed ID: 3247826
    [No Abstract]   [Full Text] [Related]  

  • 14. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
    Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
    Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential chemosensitivity of leukemic cells in the myeloid and lymphoid phases of stem cell leukemia (a case report).
    Mihál V; Hajdúch M; Dusek J; Jarosová M; Weigl E; Pikalová Z; Indrák K; Safárová M; Janostáková A
    Neoplasma; 1997; 44(2):133-6. PubMed ID: 9201294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.
    Campos L; Guyotat D; Jaffar C; Solary E; Archimbaud E; Treille D
    Eur J Haematol; 1992 May; 48(5):254-8. PubMed ID: 1353726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The leukemia stem cell.
    Estrov Z
    Cancer Treat Res; 2010; 145():1-17. PubMed ID: 20306242
    [No Abstract]   [Full Text] [Related]  

  • 18. [Neoplastic mastocytosis evolving from a poor prognosis acute myeloid leukemia].
    Chen-Liang TH; Jerez A; Florensa L; Ortuño FJ
    Med Clin (Barc); 2015 Jun; 144(12):571-2. PubMed ID: 25249393
    [No Abstract]   [Full Text] [Related]  

  • 19. HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
    Qi J; Singh S; Hua WK; Cai Q; Chao SW; Li L; Liu H; Ho Y; McDonald T; Lin A; Marcucci G; Bhatia R; Huang WJ; Chang CI; Kuo YH
    Cell Stem Cell; 2015 Nov; 17(5):597-610. PubMed ID: 26387755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of an IL-1 receptor antagonist on acute myeloid leukemia cells.
    Yin M; Gopal V; Banavali S; Gartside P; Preisler H
    Leukemia; 1992 Sep; 6(9):898-901. PubMed ID: 1387693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.